Active Clinical Trials

March 7, 2024

Now Enrolling: EA5221/ACHIEVE for Older Adults With Advanced Non-Small Cell Lung Cancer

ACHIEVE is the first randomized phase 3 study to focus on older adults with advanced non-small cell lung cancer who are treated with pembrolizumab alone compared to those treated with pembrolizumab plus chemotherapy
March 7, 2024

Trial Spotlight: Helena Yu Gives an Update on the EA5182 Trial for EGFR-Mutant Non-Small Cell Lung Cancer

This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osimertinib alone in patients with metastatic, EGFR-mutant non-small cell lung cancer
December 19, 2023

Now Enrolling: EA2222/PUMP for Patients With Colorectal Cancer That Has Spread to the Liver

This randomized phase 3 trial is testing whether second-line treatment with hepatic arterial infusion and systemic chemotherapy is more effective than systemic chemotherapy alone
October 19, 2023

Now Enrolling: Social Genomics Study EAQ211 to Examine Known Biomarkers of Elevated Health Risk in Adolescent and Young Adult Cancer Survivors

Through a series of blood tests and patient questionnaires, this prospective observational study examines how exposures to trauma and other adverse life experiences alter the activity of genes, immune cells, and subsequent health outcomes